Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Collaborative Research and Development Grants

McGill University

$40,000.00

Toward the accurate prediction of P450-mediated metabolism and adverse drug reactions using novel MM methods and QM-derived rules.

EF 2015-16

Résumé
Despite the large investment in toxicology and clinical trials of drug candidates, adverse drug reactions remain a leading cause of drug withdrawal. This form of toxicity of drugs may only affect a small fraction of the patients and is not detected in clinical trials. However, if the drug is already on the market and widely used this toxicity may be fatal. Over the years, medicinal chemists have relied on ""structural alerts"" to identify potential toxicity of drugs and more specifically idiosyncratic toxicity. These functional groups are often activated by metabolic enzymes (e.g., P450) into reactive metabolites leading to the observed toxicity. However the presence of such a functional group does not always correlate with toxicity as the bioactivation can only occur if the drug is processed (i.e., recognized) by these enzymes and although widely used this approach is not reliable (C&EN 2012, 90, 34). Thus, computational prediction has become an avenue of research and in this context we have developed a program, IMPACTS (AstraZeneca/NSERC CRD funding 01/2010-02/2012) which predicts the site of metabolism of drugs, hence whether the drug and structural alert can be processed by the major P450s. We next decided to further improve this program in two ways. On one side, we thought to use quantum mechanical techniques to improve the ligand reactivity rules and more specifically their inclination to lead to reactive metabolites once bioactivated by P450s focusing on benzene derivatives. Second we investigated the development of a conceptually novel force field to compute drug potential energies more accurately. In a proof of concept study (Chemical Computing Group/NSERC CRD 08/2013-08/2014), we have shown that these two optimizations can indeed be possible. In the current proposal, we propose to further work on these two front and complete the development of a program predicting reactive metabolites hence, adverse drug reactions.
Programme
Collaborative Research and Development Grants
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data

Tel que publié

Application id
469677-2014
Name nom
Moitessier, Nicolas
Department département
Chemistry
Organization id
61
Institution établissement
McGill University
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2015
Competition year année de concours
2014
Award amount
40000
Program id
CRDPJ
Program name en
Collaborative Research and Development Grants
Program name fr
Subventions de recherche et développement coopérative
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
504
Area of application group en
Manufacturing processes and products
Area of application group fr
Procédés et produits industriels
Area of application en
Human pharmaceuticals
Area of application fr
Produits pharmaceutiques administrables à l'homme
Research subject code
3156
Research subject group en
Theoretical physics and chemistry
Research subject group fr
Physique et chimie théoriques
Research subject en
Quantum and/or computational chemistry
Research subject fr
Chimie quantique ou par modélisation numérique
Partie
2
Nb partie
2
Application title
Toward the accurate prediction of P450-mediated metabolism and adverse drug reactions using novel MM methods and QM-derived rules.
Keyword
NSERC
Application summary
Despite the large investment in toxicology and clinical trials of drug candidates, adverse drug reactions remain a leading cause of drug withdrawal. This form of toxicity of drugs may only affect a small fraction of the patients and is not detected in clinical trials. However, if the drug is already on the market and widely used this toxicity may be fatal. Over the years, medicinal chemists have relied on ""structural alerts"" to identify potential toxicity of drugs and more specifically idiosyncratic toxicity. These functional groups are often activated by metabolic enzymes (e.g., P450) into reactive metabolites leading to the observed toxicity. However the presence of such a functional group does not always correlate with toxicity as the bioactivation can only occur if the drug is processed (i.e., recognized) by these enzymes and although widely used this approach is not reliable (C&EN 2012, 90, 34). Thus, computational prediction has become an avenue of research and in this context we have developed a program, IMPACTS (AstraZeneca/NSERC CRD funding 01/2010-02/2012) which predicts the site of metabolism of drugs, hence whether the drug and structural alert can be processed by the major P450s. We next decided to further improve this program in two ways. On one side, we thought to use quantum mechanical techniques to improve the ligand reactivity rules and more specifically their inclination to lead to reactive metabolites once bioactivated by P450s focusing on benzene derivatives. Second we investigated the development of a conceptually novel force field to compute drug potential energies more accurately. In a proof of concept study (Chemical Computing Group/NSERC CRD 08/2013-08/2014), we have shown that these two optimizations can indeed be possible. In the current proposal, we propose to further work on these two front and complete the development of a program predicting reactive metabolites hence, adverse drug reactions.